C.R. Bard (NYSE:BCR)‘s stock had its “neutral” rating restated by stock analysts at Citigroup Inc. in a report issued on Monday, American Banking & Market News reports. They currently have a $124.00 price objective on the stock, up from their previous price objective of $123.00. Citigroup Inc.’s price target indicates a potential upside of 3.08% from the stock’s previous close.
The analysts wrote, “We are adjusting our BCR estimates to reflect the continued delay in the Gore court decision and the completion of the Medafor acquisition. We are now assuming a Gore royalty start in 1Q14 and expect the Medafor acquisition to be slightly EPS accretive in 2014. For 3Q13, we have raised our Soft Tissue Repair estimates due to the full US release of Phasix resorbable mesh.”
Shares of C.R. Bard (NYSE:BCR) traded down 1.11% on Monday, hitting $118.96. 218,307 shares of the company’s stock traded hands. C.R. Bard has a 52-week low of $93.79 and a 52-week high of $121.16. The stock’s 50-day moving average is $116.8 and its 200-day moving average is $109.8. The company has a market cap of $9.416 billion and a price-to-earnings ratio of 54.36.
C.R. Bard (NYSE:BCR) last released its earnings data on Tuesday, July 23rd. The company reported $1.42 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.38 by $0.04. The company had revenue of $759.90 million for the quarter, compared to the consensus estimate of $750.91 million. During the same quarter in the prior year, the company posted $1.62 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Analysts expect that C.R. Bard will post $5.96 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, November 1st. Stockholders of record on Monday, October 21st will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date of this dividend is Thursday, October 17th.
A number of other analysts have also recently weighed in on BCR. Analysts at Needham & Company initiated coverage on shares of C.R. Bard in a research note to investors on Wednesday, September 4th. They set a “hold” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of C.R. Bard in a research note to investors on Tuesday, September 3rd. They now have a $121.00 price target on the stock. Finally, analysts at Bank of America Corp. reiterated a “buy” rating on shares of C.R. Bard in a research note to investors on Thursday, August 29th. They now have a $140.00 price target on the stock, up previously from $125.00. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and five have assigned a buy rating to the company. C.R. Bard presently has an average rating of “Hold” and an average price target of $115.71.
C. R. Bard, Inc (NYSE:BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.